



Sonodynamic inactivation of Gram-positive and Gram-negative bacteria using a Rose Bengal–antimicrobial peptide conjugate

Costley, D., Nesbitt, H., Ternan, N., Dooley, J., Huang, Y-Y., Hamblin, M. R., McHale, A. P., & Callan, J. F. (2017). Sonodynamic inactivation of Gram-positive and Gram-negative bacteria using a Rose Bengal–antimicrobial peptide conjugate. *International Journal of Antimicrobial Agents*, 49(1), 31-36. <https://doi.org/10.1016/j.ijantimicag.2016.09.034>

[Link to publication record in Ulster University Research Portal](#)

Published in:
International Journal of Antimicrobial Agents

Publication Status:
Published (in print/issue): 01/01/2017

DOI:
[10.1016/j.ijantimicag.2016.09.034](https://doi.org/10.1016/j.ijantimicag.2016.09.034)

Document Version
Author Accepted version

General rights
Copyright for the publications made accessible via Ulster University's Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Ulster University's institutional repository that provides access to Ulster's research outputs. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact pure-support@ulster.ac.uk.

Sonodynamic Inactivation of Gram Positive and Gram Negative Bacteria using a Rose Bengal-Antimicrobial Peptide Conjugate

David Costley¹, Heather Nesbitt¹, Nigel Ternan¹, James Dooley¹, Ying-Ying Huang^{2,3},
Michael R Hamblin^{2,3}, Anthony P. McHale^{1*} and John F. Callan^{1*}.

1. Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, U.K. BT52 1SA. 2. Wellman Center for Photomedicine, Massachusetts General Hospital. 3. Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA Boston, MA 02114, USA

To whom correspondence should be addressed

j.callan@ulster.ac.uk

Running title: Antimicrobial SDT.

Abstract

Combating antimicrobial resistance (AMR) is one of the most serious public health challenges facing society today. The development of new antibiotics or alternative techniques that can help combat AMR is a priority of many governments across the globe. Antimicrobial Photodynamic Therapy (APDT) is one such technique that has received considerable attention but is limited by the ability of light to penetrate deeply through human tissue reducing its effectiveness when used to treat deeply seated infections. The related technique sonodynamic therapy (SDT) has the potential to overcome this limitation given the ability of low intensity ultrasound to penetrate deeply through human tissue. In this manuscript, we have prepared a Rose Bengal-antimicrobial peptide conjugate for use in antimicrobial SDT (ASDT). We evaluate the ASDT efficacy of this conjugate upon irradiation with ultrasound in both *S. aureus* and *P. aeruginosa* bacterial strains. The ability of the conjugate to preferentially target bacteria over mammalian cells was also determined as was the ability of ultrasound to enhance the uptake of sensitisers through bacterial biofilms. Combined, the results from this study highlight ASDT as a targeted broad-spectrum modality with potential for the treatment of deeply-seated bacterial infections.

Keywords: Sonodynamic Therapy; antimicrobial; sensitiser; peptide

1. Introduction

Although the threat of antibiotic resistance has been prophesised for years, the issue has recently been described as an “apocalyptic scenario” by the UK’s chief medical officer representing “one of the most significant public health challenges facing society today”.¹ With 80% of gonorrhoeal infections now resistant to antibiotics and a reported 440,000 new cases of drug resistant tuberculosis per year, it has been suggested that we are fast approaching a post-antibiotic era.^{2,3} This threat is not confined to systemic infections with the problem equally apparent in localised wound infection. Surgical wound infections account for 25% of nosocomial infections and result in a 2.5 times longer hospital stay with additional costs of ~£5,000 per patient.⁴ Diabetic foot ulcers (DFU) and burns are equally problematic. In the US alone, 25 million people are estimated to have Diabetes Mellitus and 15-25% will develop DFU during their lifetime.⁵ Over 50% of these ulcerations will become infected resulting in increased hospital admissions, amputation rates and mortality with an estimated one in six patients dying within 1 year of their infection.⁶ The overall impact of this on both the patient and health service provider is significant and highlights an urgent need for alternative therapies.

Photodynamic therapy (PDT) is a clinical treatment that uses a combination of light, molecular oxygen and a photosensitising drug to generate a cytotoxic effect.⁷ When the sensitiser absorbs light of an appropriate wavelength, the excited triplet state interacts with molecular oxygen by electron (Type I) or energy (Type II) transfer processes that result in the generation of cytotoxic singlet oxygen and other reactive oxygen species (ROS). Because of the high reactivity and short half-life (0.04 μ s) of singlet oxygen, its diffusion radius is less than 20 nm meaning only cells close to the site of its generation are affected.⁸ While predominantly used in the treatment of cancer, antimicrobial PDT (APDT) has also received considerable interest for the treatment of microbial infections.⁹⁻¹¹ The major attraction of APDT over conventional antibiotics is that multiple antibiotic resistant (AMR) strains are as easily killed as native strains and because it results in the production of

multiple forms of ROS, resistance to PDT is less likely to occur.¹² However, PDT is severely limited by the inability of light to penetrate to depth through mammalian tissue. This is due to endogenous pigments such as haem or melanin competing for light absorption with the sensitiser and is a particular problem in localised infection where the wound area may be severely discoloured due to bruising or inflammation.¹³ Currently approved sensitisers absorb in the visible region of the electromagnetic spectrum limiting light penetration to only a few millimetres and reducing the ability of APDT to eradicate bacteria localised deeper within infected wounds.¹⁴

In recent years it has been demonstrated that many of the existing clinically-used photosensitisers can be 'activated' by ultrasound, although the precise mechanism(s) by which this occurs remain(s) unknown.¹⁵⁻¹⁸ This approach has become known as Sonodynamic Therapy (SDT). Ultrasound can be tightly focused with penetration in soft tissue up to several tens of centimetres depending on the frequency used.¹⁹ The efficacy of SDT as an anti-cancer treatment has been demonstrated in numerous pre-clinical and clinical studies.²⁰⁻²³ Antimicrobial SDT (ASDT) has also emerged as an active area of research but reports to date have used clinically unsuitable ultrasound equipment / conditions and have not explored the potential damage of the treatment on host tissue.²⁴⁻²⁶ As is the case for APDT, a major challenge for ASDT is specifically targeting the sensitiser to bacterial cells to reduce collateral damage to host tissue. A surgical site infection can be defined as a suppurating wound containing a variety of components such as host tissue (skin cells, muscle cells and extracellular matrix components), immune cells and bacterial cells (both live and dead).^{27,28} The bacterial load can be as low as 10^5 bacteria (i.e. μg quantities) per gram of tissue meaning the majority of this complex environment is host tissue essential in the healing process.²⁹ As the cytotoxic agent(s) involved in APDT / ASDT are indiscriminate in their action on host or bacterial cells, it is imperative the sensitiser is preferentially directed to bacterial cells rather than host cells before activation with light or ultrasound. One method to achieve sensitiser selectivity is to exploit the differential binding

exhibited by cationic species to the cell wall of bacterial and mammalian cells. For example, it has been demonstrated that light irradiation of wounds in mice treated with a poly-L-lysine-chlorin(e6) conjugate exhibited a greater bacterial kill and less host tissue damage than the free sensitiser alone.³⁰ Similarly, when the antimicrobial peptide (KLAKLAK)₂ was conjugated to the sensitiser eosin, its antimicrobial photodynamic activity was enhanced with negligible photo-damage observed to normal cells.³¹

Inspired by these results, we have developed a Rose Bengal-(KLAKLAK)₂ conjugate for use in targeted ASDT. The potential of the conjugate to generate ROS during exposure to ultrasound was determined in cell-free solution and the antimicrobial efficacy was established using both *Staphylococcus aureus* and *Pseudomonas aeruginosa* as target microorganisms. The ability of the conjugate to preferentially target bacteria over healthy mammalian cells was also determined. Finally, the effectiveness of ultrasound to enhance the diffusion of sensitisers through bacterial biofilms was investigated.

2. Results and Discussion

The Rose Bengal-C(KLAKLAK)₂ conjugate was prepared by first synthesising the C(KLAKLAK)₂ peptide using Fmoc solid phase peptide synthesis on Rink Amide resin. In parallel, a carboxylic acid derivative of Rose Bengal was also prepared by reacting Rose Bengal with 1-bromooctanoic acid. This carboxylic acid derivative was added to the N-terminus of C(KLAKLAK)₂ while still on the resin using standard peptide coupling reagents (i.e. HOBt / TBTU). The Rose Bengal-C(KLAKLAK)₂ conjugate was then cleaved from the resin and purified using preparative reverse phase HPLC. Product formation was confirmed using MALDI-TOF and positive electrospray mass spectrometry (Fig S1).

The ability of the Rose Bengal-C(KLAKLAK)₂ conjugate to generate ROS upon exposure to low intensity ultrasound was determined using the chromogenic ROS probe 1,3-diphenylisobenzofuran (DPBF).³² DPBF has an intense absorbance band centred at 410 nm in its native furan form but is readily bleached by ROS to the corresponding di-ketone. This conversion to the di-ketone is accompanied by a loss in absorbance at 410 nm that can be used to determine the amount of ROS produced. Solutions containing either Rose Bengal or Rose Bengal-C(KLAKLAK)₂ and DPBF were treated with ultrasound for 30 min and the DPBF absorbance at 410 nm measured every 5 min. The results are shown in figure 1 and show a significant reduction in DPBF absorbance for both Rose Bengal or Rose Bengal-C(KLAKLAK)₂ treated with ultrasound relative to the controls indicating efficient ROS production in the ultrasonic field. In addition, the almost identical profile observed for both Rose Bengal and Rose Bengal-C(KLAKLAK)₂ suggests the presence of the peptide does not inhibit ultrasound-induced ROS production by the sensitiser.

To determine the antimicrobial potential of this ROS generation, two candidate bacterial strains, Gram positive *S. aureus* and Gram negative *P. aeruginosa*, were subjected to ASDT treatment. In each case, suspensions containing 10⁸ bacteria were added to the wells of a 96-well plate and incubated with 10 µM Rose Bengal or Rose Bengal-C(KLAKLAK)₂ for 30

min. The wells were then treated with ultrasound from the underside of the plate for either 10 min (*S. aureus*) or 6 min (*P. aeruginosa*). Following treatment, the number of viable bacteria remaining was determined and expressed as CFU/mL. The results, shown in figure 2, reveal that ultrasound treatment of *S. aureus* produces only a minor reduction (~0.5 log) in bacterial number that was not statistically significant. Treatment of *S. aureus* with Rose Bengal-C(KLAKLAK)₂ in the absence of ultrasound produced an ~1 log reduction in bacterial number. This reduction was attributed to the antimicrobial effect from the AMP component of the Rose Bengal-C(KLAKLAK)₂ conjugate as Rose Bengal alone in the absence of ultrasound produced no change in bacterial number (data not shown). The magnitude of this reduction is consistent with other literature where (KLAKLAK)₂ alone has been shown to possess little activity against Gram positive bacteria.³¹ However, when Rose Bengal-C(KLAKLAK)₂ was combined with ultrasound treatment, a statistically significant 5 log reduction in bacterial number was observed. This suggests that the ROS generated upon interaction of ultrasound with the Rose Bengal component of Rose Bengal-C(KLAKLAK)₂ produces the desired antimicrobial effect. When this experiment was repeated using the same concentration of Rose Bengal (i.e. without AMP attached) and the same ultrasound conditions, the reduction in bacterial numbers was approximately one log less than for Rose Bengal-C(KLAKLAK)₂ plus ultrasound. This difference, while not statistically significant, suggests the slight antimicrobial effect observed for Rose Bengal-C(KLAKLAK)₂ alone (i.e. no ultrasound) complements the ASDT effect of Rose Bengal.

It is generally considered that PDT is more toxic to Gram positive than Gram negative bacteria and it has been suggested that this is due to structural differences in cell wall composition.³³ Given that both the sensitisers used and the cytotoxic species generated (i.e. ROS) are the same in PDT and SDT, one would expect that Gram negative bacteria would also be more difficult to kill using SDT. Indeed, when *P. aeruginosa* was treated with Rose Bengal and ultrasound, only a minor reduction in bacterial number was observed (~ 0.5 log) which was considerably lower than for *S. aureus*. However, when *P. aeruginosa* was treated

with the Rose Bengal-C(KLAKLAK)₂ conjugate and ultrasound the results were even more dramatic than for *S. aureus*, with a 7 log reduction in CFU observed (Fig.2b). This large reduction in bacterial number cannot be explained by the antimicrobial nature of the peptide alone as treatment of *P. aeruginosa* with Rose Bengal-C(KLAKLAK)₂ in the absence of ultrasound produced a much lower 3.5 log reduction in bacterial number, suggesting the peptide positions the sensitiser close enough to the bacteria to exert its cytotoxic effect during ultrasound irradiation. To probe this interaction further, we incubated suspensions of both *S. aureus* and *P. aeruginosa* with different amounts of the Rose Bengal-C(KLAKLAK)₂ conjugate and measured the zeta potential before and after conjugate addition. Both bacterial strains showed strongly negative zeta potentials (-42.0 and -27.0 mV respectively) which are consistent with literature precedent.^{34,35} Upon addition of increasing amounts of Rose Bengal-C(KLAKLAK)₂, the net charge of both bacteria increased but with significantly different magnitudes (Fig.3). For example, addition of 10 µM Rose Bengal-C(KLAKLAK)₂ to *P. aeruginosa* resulted in a 2.0 mV increase in zeta potential while for *S. aureus* an increase of 29.7 mV was observed. Indeed, only when 50 µM Rose Bengal-C(KLAKLAK)₂ was added to *P. aeruginosa* did the charge become positive while for *S. aureus* this occurred after only 10 µM. These results confirm a direct interaction between the positively charged peptide and negatively charged bacterial cell wall with *P. aeruginosa* requiring a significantly greater number of Rose Bengal-C(KLAKLAK)₂ molecules to bind in order to titrate the more negative surface charge.

Systemic delivery of sensitisers is not normally considered in APDT as damage to capillaries and host cells directly supplied by them is undesirable.³⁶ Therefore, while local administration is preferred, this form of delivery still requires the sensitiser to be targeted to bacteria so that collateral damage to host tissue crucial to the healing process can be minimised. To determine the ability of Rose Bengal-C(KLAKLAK)₂ to preferentially target bacteria over mammalian cells, solutions containing Rose Bengal or Rose Bengal-C(KLAKLAK)₂ were incubated with suspensions containing *S. aureus*, *P. aeruginosa* or

human fibroblast (HS27) cells for either 10, 20 or 30 min. Following incubation, the suspensions were centrifuged, the cells lysed and the Rose Bengal concentration determined using UV-Vis spectroscopy. The results are shown in Fig 4 and reveal a significantly enhanced uptake of the Rose Bengal-C(KLAKLAK)₂ in both bacteria compared to the Hs27 cells at the time points tested. Indeed, the uptake of Rose Bengal-C(KLAKLAK)₂ conjugate was also higher than Rose Bengal in both bacteria while it was generally lower in the Hs-27 cells which is ideal for bacterial targeting.

The presence of biofilms is a significant challenge associated with the local delivery of sensitiser drugs as it can act as a barrier between the applied sensitiser and bacteria. With as many as 80% of SSI's involving a microbial biofilm, strategies that can enhance dispersion of drugs through biofilms offer a significant advantage. It has been demonstrated that in addition to increasing the permeability of membranes through sonoporation, shear forces induced by ultrasound generates pores in the architecture of biofilms, enhancing the effectiveness of antibiotic treatment.³⁷ To test this hypothesis, we generated *P. aeruginosa* biofilms on the surface of trans-well inserts and tested the diffusion of Rose Bengal through the biofilm in the presence and absence of ultrasound (Fig 5a). Preliminary data (Fig 5b) show that pre-treatment of the biofilm with low intensity ultrasound for 5 min before addition of Rose Bengal produced a 2.6-fold increase in sensitiser diffusion through the biofilm compared to the untreated biofilm control. These results suggest that ultrasound can facilitate the dispersion of sensitisers through biofilms and potentially improve the efficacy of ASDT.

Having established the effectiveness of the SDT approach *in vitro* we were also interested if a similar effect would be observed *in vivo*. To determine this, wound abrasions (0.5 cm²) were established in the dorsum of Balb/c mice and inoculated with a bioluminescent strain of *P. aeruginosa*. Once the infection had established, bioluminescent images were recorded using an IVIS whole body imaging system. The wound was then treated with a PBS solution

containing the Rose Bengal-C(KLAKLAK)₂ conjugate (4.5mg/kg) and 10 min later exposed to ultrasound. Bioluminescent images were then recorded 1 h and 24 h after ultrasound treatment. Control groups involving no treatment or treatment with Rose Bengal-C(KLAKLAK)₂ or ultrasound alone were also undertaken for comparative purposes. Representative images of the mice are shown in figure 6 and reveal substantial reductions in bioluminescent intensity for mice treated with the conjugate alone or SDT, with the SDT image being less intense, particularly after 24h. In contrast, the bioluminescent intensity of the untreated and ultrasound only groups were substantially more intense than the Rose Bengal-C(KLAKLAK)₂ or SDT treated animals. This pattern follows a similar trend to the results obtained for the *in vitro* experiments undertaken using *P. aeruginosa* where Rose Bengal-C(KLAKLAK)₂ alone produced a modest 3.5 log reduction while SDT treatment resulted in a much greater 7 log reduction. It was also apparent from the images presented in Figure 6 that the size of the wound 24 h following SDT treatment was much smaller when compared to 1 h following SDT treatment suggesting a degree of wound healing, a feature that was not apparent in any of the other groups. While there is an obvious limitation in the small sample size used in these experiments, the results do suggest that SDT using Rose Bengal-C(KLAKLAK)₂ is capable of substantially reducing bacterial burden in an *in vivo* model of localised infection. Interestingly the results also suggest that our approach does not elicit any collateral damage on host tissues. We are currently designing a larger animal study involving both *MRSA* and *P. aeruginosa* infection models and will report on this in due course.

In conclusion, a Rose Bengal-C(KLAKLAK)₂ conjugate has been prepared for use in targeted ASDT. A broad-spectrum ASDT effect was observed when the conjugate was used to treat *S. aureus* and *P. aeruginosa* in the presence of low intensity ultrasound. The conjugate also displayed improved uptake by these bacterial strains when compared to a mammalian cell line which promises to minimise damage to host tissue when considering *in vivo* ASDT applications. In addition, pre-treatment of a *P. aeruginosa* biofilm with low

intensity ultrasound before application of Rose Bengal enhanced diffusion of the sensitiser through the biofilm. A preliminary pilot *in vivo* experiment provided qualitative evidence of a substantial reduction in bacterial burden without collateral damage to host tissues when a *P. aeruginosa* infected wound was treated with SDT using the Rose Bengal-C(KLAKLAK)₂ conjugate. Combined, these results suggest that ASDT using Rose Bengal-C(KLAKLAK)₂ is an effective broad-spectrum antimicrobial technique with the potential to activate sensitisers at a much greater depth in human tissue than APDT enabling the treatment of more deep-seated infections.

Acknowledgements

JFC thanks Norbrook Laboratories Ltd for an endowed chair.

Declarations

Funding: None

Competing Interests: None

Ethical Approval: Not required

Supporting Information

Containing detailed materials & methods and characterisation of Rose Bengal-C(KLAKLAK)₂ conjugate.

References

1. Davies S. Annual report of the chief medical officer 2011: Volume two.
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/138331/CMO_Annual_Report_Volume_2_2011.pdf. Updated 2013. Accessed October 21, 2015.
2. Ison CA. Antimicrobial agents and gonorrhoea: Therapeutic choice, resistance and susceptibility testing. *Genitourin Med*. 1996;72(4):253-257.
3. World Health Organisation. Tuberculosis global Facts Geneva: World health organization; 2011. http://www.who.int/tb/publications/2011/factsheet_tb_2011.pdf. Updated 2012. Accessed November 10, 2015.
4. Jenks P, Laurent M, McQuarry S, Watkins R. Clinical and economic burden of surgical site infection (SSI) and predicted financial consequences of elimination of SSI from an english hospital. *J Hosp Infect*. 2014;86(1):24-33.
5. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. *JAMA*. 2005;293(2):217-228.
6. Ogbera AO, Chinenye S, Onyekwere A, Fasanmade O. Prognostic indices of diabetes mortality. *Ethn Dis*. 2007;17(4):721-725.
7. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. *J Natl Cancer Inst*. 1998;90(12):889-905.
8. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: Part one—photosensitizers, photochemistry and cellular localization. *Photodiagnosis and photodynamic therapy*. 2004;1(4):279-293.
9. Hamblin MR, Hasan T. Photodynamic therapy: A new antimicrobial approach to infectious disease? *Photochemical & Photobiological Sciences*. 2004;3(5):436-450.
10. Garcez AS, Ribeiro MS, Tegos GP, Núñez SC, Jorge AO, Hamblin MR. Antimicrobial photodynamic therapy combined with conventional endodontic treatment to eliminate root canal biofilm infection. *Lasers Surg Med*. 2007;39(1):59-66.
11. Pagonis TC, Chen J, Fontana CR, et al. Nanoparticle-based endodontic antimicrobial photodynamic therapy. *J Endod*. 2010;36(2):322-328.

308 12. Tavares A, Carvalho C, Faustino MA, et al. Antimicrobial photodynamic therapy: Study of
309 bacterial recovery viability and potential development of resistance after treatment. *Marine*
310 *drugs*. 2010;8(1):91-105.

311 13. Huang Z, Xu H, Meyers AD, et al. Photodynamic therapy for treatment of solid tumors--
312 potential and technical challenges. *Technol Cancer Res Treat*. 2008;7(4):309-320.

313 14. O'Riordan K, Akilov OE, Hasan T. The potential for photodynamic therapy in the
314 treatment of localized infections. *Photodiagnosis and Photodynamic Therapy*. 2005;2(4):247-
315 262.

316 15. Miyoshi N, Mišík V, Fukuda M, Riesz P. Effect of gallium-porphyrin analogue ATX-70 on
317 nitroxide formation from a cyclic secondary amine by ultrasound: On the mechanism of
318 sonodynamic activation. *Radiat Res*. 1995;143(2):194-202.

319 16. Miyoshi N, Igarashi T, Riesz P. Evidence against singlet oxygen formation by sonolysis
320 of aqueous oxygen-saturated solutions of hematoporphyrin and rose bengal: The
321 mechanism of sonodynamic therapy. *Ultrason Sonochem*. 2000;7(3):121-124.

322 17. Mišík V, Riesz P. Free radical intermediates in sonodynamic therapy. *Ann N Y Acad*
323 *Sci*. 2000;899(1):335-348.

324 18. Tomankova K, Kolarova H, Kolar P, Kejlova K, Jirova D. Study of cytotoxic effect of
325 photodynamically and sonodynamically activated sensitizers in vitro. *Toxicology in Vitro*.
326 2009;23(8):1465-1471.

327 19. ter Haar G. Therapeutic applications of ultrasound. *Prog Biophys Mol Biol*.
328 2007;93(1):111-129.

329 20. Nonaka M, Yamamoto M, Yoshino S, Umemura S, Sasaki K, Fukushima T.
330 Sonodynamic therapy consisting of focused ultrasound and a photosensitizer causes a
331 selective antitumor effect in a rat intracranial glioma model. *Anticancer Res*. 2009;29(3):943-
332 950.

333 21. Kenyon JN, Fulle RJ, Lewis TJ. Activated cancer therapy using light and ultrasound-A
334 case series of sonodynamic photodynamic therapy in 115 patients over a 4 year period.
335 *Current Drug Therapy*. 2009;4(3):179-193.

336 22. Wang X, Zhang W, Xu Z, Luo Y, Mitchell D, Moss RW. Sonodynamic and photodynamic
337 therapy in advanced breast carcinoma: A report of 3 cases. *Integr Cancer Ther.*
338 2009;8(3):283-287.

339 23. McEwan C, Owen J, Stride E, et al. Oxygen carrying microbubbles for enhanced
340 sonodynamic therapy of hypoxic tumours. *J Controlled Release.* 2015;203:51-56.

341 24. Xu C, Dong J, Ip M, Wang X, Leung AW. Sonodynamic action of chlorin e6 on
342 staphylococcus aureus and escherichia coli. *Ultrasonics.* 2016;64:54-57.

343 25. Wang X, Leung AW, Hua H, Xu C, Ip M. Sonodynamic action of hypocrellin B on biofilm-
344 producing staphylococcus epidermidis in planktonic condition. *J Acoust Soc Am.*
345 2015;138(4):2548-2553.

346 26. Zhuang D, Hou C, Bi L, et al. Sonodynamic effects of hematoporphyrin monomethyl
347 ether on staphylococcus aureus in vitro. *FEMS Microbiol Lett.* 2014;361(2):174-180.

348 27. Garcez AS, Neto JGA, Sellera DP, Fregnani E. Effects of antimicrobial photodynamic
349 therapy and surgical endodontic treatment on the bacterial load reduction and periapical
350 lesion healing. three years follow up. *Photodiagnosis and photodynamic therapy.* 2015.

351 28. Zhang Y, Zhu Y, Gupta A, et al. Antimicrobial blue light therapy for multidrug-resistant
352 acinetobacter baumannii infection in a mouse burn model: Implications for prophylaxis and
353 treatment of combat-related wound infections. *J Infect Dis.* 2014;209(12):1963-1971.


354 29. Turtiainen J, Hakala T, Hakkarainen T, Karhukorpi J. The impact of surgical wound
355 bacterial colonization on the incidence of surgical site infection after lower limb vascular
356 surgery: A prospective observational study. *European Journal of Vascular and Endovascular*
357 *Surgery.* 2014;47(4):411-417.

358 30. Soukos NS, Hamblin MR, Hasan T. The effect of charge on cellular uptake and
359 phototoxicity of polylysine Chlorine6Conjugates. *Photochem Photobiol.* 1997;65(4):723-729.

360 31. Johnson GA, Muthukrishnan N, Pellois J. Photoinactivation of gram positive and gram
361 negative bacteria with the antimicrobial peptide (KLAKLAK) 2 conjugated to the hydrophilic
362 photosensitizer eosin Y. *Bioconjug Chem.* 2012;24(1):114-123.


32. McDonnell SO, Hall MJ, Allen LT, Byrne A, Gallagher WM, O'Shea DF. Supramolecular photonic therapeutic agents. *J Am Chem Soc.* 2005;127(47):16360-16361.
33. Malik Z, Ladan H, Nitzan Y. Photodynamic inactivation of gram-negative bacteria: Problems and possible solutions. *Journal of Photochemistry and Photobiology B: Biology.* 1992;14(3):262-266.
34. Wilson WW, Wade MM, Holman SC, Champlin FR. Status of methods for assessing bacterial cell surface charge properties based on zeta potential measurements. *J Microbiol Methods.* 2001;43(3):153-164.
35. Soni KA, Balasubramanian AK, Beskok A, Pillai SD. Zeta potential of selected bacteria in drinking water when dead, starved, or exposed to minimal and rich culture media. *Curr Microbiol.* 2008;56(1):93-97.
36. Berg K, Golab J, Korbelik M, Russell D. Drug delivery technologies and immunological aspects of photodynamic therapy. *Photochemical & Photobiological Sciences.* 2011;10(5):647-648.
37. He N, Hu J, Liu H, et al. Enhancement of vancomycin activity against biofilms by using ultrasound-targeted microbubble destruction. *Antimicrob Agents Chemother.* 2011;55(11):5331-5337.

Figures and Diagrams



Scheme 1 Structure of Rose Bengal-C(KLAKLAK)₂.

414



415

416 **Figure 1** Plot of DPBF absorbance at 410 nm against time for solutions containing (i) Rose
 417 Bengal (ii) Rose Bengal-C(KLAKLAK)₂ conjugate (iii) DPBF alone plus ultrasound treatment
 418 (iv) Rose Bengal plus ultrasound treatment and (v) Rose Bengal-C(KLAKLAK)₂ conjugate plus
 419 ultrasound treatment.

420

421

422

423

424

425

426

427

428

429

430

431

432




Figure 2 Plot of CFU/mL after treatment of (a) *S. aureus* and (b) *P. aeruginosa* with RB-C(KLAKLAK)₂ (P), Rose Bengal (RB) with / without ultrasound (+/- U). [RB-C(KLAKLAK)₂] = [RB] = 10 μ M. Ultrasound conditions: 1 MHz, 3Wcm⁻², 10 min, 50 % duty cycle for *S. aureus* and 1 MHz, 3Wcm⁻², 6 min, 50 % duty cycle for *P. aeruginosa*. * represents $P \leq 0.05$, ** represents $P \leq 0.01$




Figure 3 Plot of zeta potential for suspensions of *P. aeruginosa* (shaded columns) and *S. aureus* (clear columns) recorded after addition of increasing amounts of RB-C(KLAKLAK)₂.






Figure 4 Plot of nmol of Rose Bengal per mg protein for suspensions of *S. aureus* (circles), *P. aeruginosa* (triangles) and HS27 RB cells (squares) incubated with RB (filled symbols) or RB-C(KLAKLAK)₂ (open symbols) for 10, 20 or 30 mins. (# represents $P \leq 0.001$ with respect to uptake by RB alone and $P \leq 0.001$ with respect to RB-C(KLAKLAK)₂ uptake in HS27 cells). (≠ represents $P \leq 0.01$ with respect to uptake by RB alone and $P \leq 0.01$ with respect to RB-C(KLAKLAK)₂ uptake in HS27 cells).

463



464




465

466

467 **Figure 5** (a) Schematic representation of biofilm diffusion experiment. *P.aeruginosa* biofilms
 468 were generated on transwell inserts. The inserts were placed in wells containing PBS buffer
 469 and the base of each well irradiated (or not) with low intensity ultrasound. RB solution was
 470 added to the donor insert and the concentration of RB in the receiving PBS solution
 471 determined at various time points using UV-Vis spectroscopy (b) plot of RB absorbance
 472 against time for experiments performed in (a) ■ = wells pre-treated with US and ♦ = wells not
 473 pre- treated with US. ** represents $P \leq 0.01$

474

475



476

477 **Figure 6** Whole body bioluminescent images of mice bearing 0.5 cm² wounds infected with
 478 *P.aeruginosa* and receiving (i) no treatment (ii) ultrasound only (iii) RB-C(KLAKLAK)₂ only or
 479 (iv) SDT, with images recorded immediately before, 1 h and 24 h after treatment.